KALA BIO, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $3.9M | $11.2M | $6.4M | $6.1M | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | $18.4M | $27.3M | $29.0M |
| SG&A Expense | $23.6M | $18.3M | $20.6M | $65.0M | $105.1M | $81.1M | $65.0M | $10.9M |
| Operating Income | $-39.2M | $-41.0M | $-39.7M | $-81.7M | $-130.2M | $-96.2M | $-88.2M | $-39.9M |
| Operating Margin | — | — | — | -2,099.3% | -1,158.8% | -1,512.6% | -1,452.5% | — |
| Interest Expense | — | — | $5.8M | $7.3M | $8.4M | $8.6M | $8.5M | $1.0M |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-27.0M | $-38.5M | $-42.2M | $-44.8M | $-142.6M | $-104.3M | $-94.3M | $-42.2M |
| Net Margin | — | — | — | -1,151.6% | -1,268.7% | -1,639.8% | -1,553.3% | — |
| EPS (Basic) | $-3.31 | $-5.08 | $-8.68 | $-14.74 | $-54.16 | $-1.00 | $-1.38 | $-1.86 |
| EPS (Diluted) | $-3.31 | $-5.08 | $-8.68 | $-14.74 | $-54.16 | $-1.00 | $-1.38 | $-1.86 |
| Shares Outstanding (Basic) | 8.1M | 7.6M | 4.9M | 3.0M | 2.6M | 104.8M | 72.2M | 49.1M |
| Shares Outstanding (Diluted) | 8.1M | 7.6M | 4.9M | 3.0M | 2.6M | 104.8M | 72.2M | 49.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |